Why Sanofi is under pressure
Sanofi prematurely halts a late-stage trial of an experimental antibody for a rare autoimmune disease after interim results indicate insufficient efficacy, causing the stock to slide on the market amid analysts’ concerns about the group’s pipeline. Facts and comments.
